Developed under the direction and sponsorship of EMD Serono, Inc.

20+ years of combined clinical trial and real-world experience1-3

DOWNLOAD SERVICE REQUEST FORM

140,000+ US patients treated since approval

52 million+ estimated doses since approval

0 mentions of progressive multifocal leukoencephalopathy included in Rebif labeling

  • Common adverse events were consistent across PRISMS and EVIDENCE clinical trials
  • Serious and life-threatening adverse reactions have been reported with interferon beta products, including Rebif:
    • Depression, suicidal ideation, and suicide attempts
    • Severe liver injury, including some cases of hepatic failure requiring liver transplantation
    • Cases of thrombotic microangiopathy, some fatal

IMPORTANT SAFETY INFORMATION

Decreased peripheral blood counts in all cell lines, including pancytopenia, have been reported in Rebif-treated patients. In controlled clinical trials, leukopenia occurred at a higher frequency in Rebif-treated patients than in placebo and Avonex-treated patients. Thrombocytopenia and anemia occurred more frequently in 44 mcg Rebif-treated patients than in placebo-treated patients. Patients should be monitored for symptoms or signs of decreased blood counts. Monitoring of complete blood and differential white blood cell counts is also recommended.

The most common side effects with Rebif are injection-site disorders, headaches, influenza-like symptoms, abdominal pain, depression, elevated liver enzymes, and hematologic abnormalities.

Your eligible patients may receive either Rebif for a co-pay of $0 or free medication for 1 year

$0 co-pay*

For Rebif For Eligible
Patients Who Have Insurance

*Or co-insurance. Some limitations required by law. Patients covered by federal and state healthcare programs are not eligible for assistance.

or

For eligible* patients who don't have insurance or are underinsured

Free medication
for 1 year

*No need to meet financial requirements or verify income. Before the first year has ended, MS LifeLines® will help eligible patients apply for assistance programs to avoid any lapse in coverage. Patients covered by federal and state healthcare programs are not eligible for this program.

Over 4 million calls handled by MS LifeLines®2
1-877-447-3243 • Hours 24/7

MS LifeLines®: 24/7 individualized support to help patients start and stay on therapy

  • One-on-one injection training by MS LifeLines registered nurses; your office notified when patient training is completed
  • Reimbursement specialist assesses coverage and provides support for reimbursement
  • MS LifeLines Nurses maintain frequent contact with patients during first year on therapy: monthly for first 6 months and bimonthly thereafter*

*With patient consent; subject to change.

  • Prescribe Rebif using a service request form. Just print it, fill it out with your patient, and fax it to 1-866-227-3243 to get started. Download service request form
  • Prescribe online: iAssist is a free, full-service, online prescribing system that enables paperless prescriptions. Register now

INDICATION

Rebif is indicated for the treatment of patients with relapsing forms of MS to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability.

IMPORTANT SAFETY INFORMATION

Rebif is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation.

Rebif should be used with caution in patients with depression, a condition that is common in people with multiple sclerosis. Depression, suicidal ideation, and suicide attempts have been reported to occur with increased frequency in patients receiving interferon compounds, including Rebif.

Severe liver injury, including some cases of hepatic failure requiring liver transplantation, has been reported rarely in patients taking Rebif. The potential for liver injury should be considered when used in combination with other products associated with liver injury. Monitor liver function tests and patients for signs and symptoms of hepatic injury. Consider discontinuing Rebif if hepatic injury occurs.

Anaphylaxis and other allergic reactions (some severe) have been reported as a rare complication of Rebif. Discontinue Rebif if anaphylaxis occurs.

In controlled clinical trials, injection site reactions occurred more frequently in Rebif-treated patients than in placebo-treated and Avonex-treated patients. Injection site reactions including injection site pain, erythema, edema, cellulitis, abscess, and necrosis have been reported in the postmarketing setting. Do not administer Rebif into affected area until fully healed; if multiple lesions occur, discontinue Rebif until skin lesions are healed.

Decreased peripheral blood counts in all cell lines, including pancytopenia, have been reported in Rebif-treated patients. In controlled clinical trials, leukopenia occurred at a higher frequency in Rebif-treated patients than in placebo and Avonex-treated patients. Thrombocytopenia and anemia occurred more frequently in 44 mcg Rebif-treated patients than in placebo-treated patients. Patients should be monitored for symptoms or signs of decreased blood counts. Monitoring of complete blood and differential white blood cell counts is also recommended.

Cases of thrombotic microangiopathy (TMA), some fatal, have been reported with interferon beta products, including Rebif, up to several weeks or years after starting therapy. Discontinue Rebif if clinical symptoms and laboratory findings consistent with TMA occur, and manage as clinically indicated.

Caution should be exercised when administering Rebif to patients with pre-existing seizure disorders. Seizures have been temporally associated with the use of beta interferons, including Rebif, in clinical trials and in postmarketing reports.

The most common side effects with Rebif are injection-site disorders, headaches, influenza-like symptoms, abdominal pain, depression, elevated liver enzymes, and hematologic abnormalities.

There are no adequate and well-controlled studies in pregnant women. Rebif should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

INDICATION

Rebif is indicated for the treatment of patients with relapsing forms of MS to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability.

Please see Rebif Prescribing Information and Medication Guide.

References: 1. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-1504. 2. Data on file. EMD Serono, Inc. 3. Rebif® [Prescribing Information]. Rockland, MA: EMD Serono, Inc.

Rebif and MS LifeLines are registered trademarks of EMD Serono, Inc. or its affiliates. Avonex is a registered trademark of Biogen.

©2017 EMD Serono, Inc. All rights reserved. US/REB/0217/0042(1) 07/17